(IN BRIEF) AstraZeneca’s Trixeo Aerosphere has received a positive opinion from the EMA’s CHMP for use with a new propellant that offers a 99.9% reduction in Global Warming Potential compared to traditional formulations. Trixeo becomes the first pressurised metered-dose inhaler … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged Ambition Zero Carbon, AMPLIFY Phase III trial, AstraZeneca, Barbara Eichhorst, Breztri, BTK inhibitor, budesonide, Calquence, chemoimmunotherapy, CHMP, chronic lymphocytic leukaemia, climate action in pharma, clinical trial, CLL, COPD, Dave Fredrickson, EMA, environmental sustainability, European approval, European Commission approval, European Union, fixed-duration regimen, formoterol fumarate, Frederik Trinkmann, glycopyrronium, hematologic diseases, hematology, Honeywell, inhalers, leukemia, low GWP, next-generation propellant, obinutuzumab, oncology, pMDI, progression-free survival, Respiratory Care, Ruud Dobber, Susanna Palkonen, Sustainable Healthcare, treatment option, Trixeo Aerosphere, venetoclax
(IN BRIEF) AstraZeneca’s Calquence, in combination with venetoclax, with or without obinutuzumab, has been approved by the European Commission for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL). The approval follows the positive results from the … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged AMPLIFY Phase III trial, AstraZeneca, Barbara Eichhorst, BTK inhibitor, Calquence, chemoimmunotherapy, chronic lymphocytic leukaemia, clinical trial, CLL, Dave Fredrickson, European Commission approval, European Union, fixed-duration regimen, hematologic diseases, hematology, leukemia, obinutuzumab, oncology, progression-free survival, treatment option, venetoclax
(IN BRIEF) AstraZeneca is set to unveil promising data at the 65th American Society of Hematology (ASH) Annual Meeting, highlighting its expanding hematology pipeline and the enduring effectiveness of Calquence in treating chronic lymphocytic leukemia (CLL). The presentation includes six-year … Read the full press release
(PRESS RELEASE) STOCKHOLM, 2-Sep-2021 — /EuropaWire/ — Investor AB (STO: INVE-B), a Swedish investment and holding company founded in 1916, has announced its support for the Agnafit Bidco¹’s bid for Sobi (Swedish Orphan Biovitrum AB). The company has undertaken to … Read the full press release
Posted in Business, Healthcare, Investment, Management, News, Pharma & Biotech, Science, Sweden, Technology
Tagged acquisitions, Advent International, Advent International Corporation, Agnafit Bidco, Aurora Investments Pte Ltd, Biovitrum, GIC Pte Ltd., GIC Special Investments Pte Ltd, Healthcare, hematology, hemophilia, immunology, Investor AB, Johan Forssell, public offer, shares, Sobi, Swedish Orphan Biovitrum AB, Swedish Orphan International
The new immunotherapy will be tested in humans as soon as possible (PRESS RELEASE) ZURICH, 8-May-2020 — /EuropaWire/ — University of Zurich researchers have announced a study that is showing how hematopoietic stem cells from a healthy donor can help … Read the full press release
Posted in Education, Healthcare, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged acute leukemia, Acute myeloid leukemia, Alexander Simonis, AML, Antonia M. Müller, blood stem cells, bone marrow, Burkhard Becher, C. Matthias Wilk, Cancer, cancerous hematopoietic stem cells, CAR-T, chemotherapy, Chiara F. Magnani, Christian Münz, Dario Neri, Donal McHugh, ETH Zurich, genetic modification, hematology, Hematopoietic stem cells, immunotherapy, Jonathan D. Kiefer, Juliane Friemel, leukemia, Maries van den Broek, Markus G. Manz, Markus Manz, Nicolás Nuñez, Norman F. Russkamp, oncology, platelets, radiotherapy, red blood cells, Renier Myburgh, Surema Pfister, transplant, University Hospital Zurich, University of Zurich, white blood cells
27 scientific presentations, including long-term data from Calquence in mantle cell lymphoma and updated early-phase trial results in chronic lymphocytic leukaemia New data on six medicines and potential new medicines across a variety of blood cancers demonstrate breadth of haematology portfolio … Read the full press release
Posted in Healthcare, Pharma & Biotech, United Kingdom
Tagged Acerta Pharma, AstraZeneca, biologics, blood cancer, haematology, hematology, leukaemia, lymphoma, MedImmune
In two Phase III studies, Jakavi ® reduced the risk of death and maintained spleen reductions at three years compared to conventional therapy and placebo Similar survival benefit seen in patients with and without high-risk mutations Separate analysis shows Jakavi may increase … Read the full press release
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?